T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FMBI
1901
DELISTED
First Midwest Bancorp Inc/IL
FMBI
| $1.28M | ﹤0.01% |
62,405
-10,405
| -14% | -$208K |
|
1902
First Bancorp
FBP
$4.52B
| $1.28M | ﹤0.01% |
92,690
-3,438
| -4% | -$47.3K |
|
1903
Evertec
EVTC
$1.89B
| $1.27M | ﹤0.01% |
25,424
-999
| -4% | -$46.2K |
|
1904
City Holding Co
CHCO
$2.08B
| $1.27M | ﹤0.01% |
15,520
-2,228
| -13% | -$179K |
|
1905
Nektar Therapeutics
NKTR
$2.53B
| $1.27M | ﹤0.01% |
6,263
-2,180
| -26% | -$473K |
|
1906
Assured Guaranty
AGO
$3.37B
| $1.27M | ﹤0.01% |
25,257
-2,085
| -8% | -$107K |
|
1907
Grand Canyon Education
LOPE
$3.74B
| $1.27M | ﹤0.01% |
14,777
-58,344
| -80% | -$4.81M |
|
|
CLDT
1908
Chatham Lodging
CLDT
$600M
| $1.27M | ﹤0.01% |
92,260
-2,300
| -2% | -$29.6K |
|
|
UMPQ
1909
DELISTED
Umpqua Holdings Corp
UMPQ
| $1.27M | ﹤0.01% |
65,816
-3,778
| -5% | -$76.3K |
|
1910
CBIZ
CBZ
$2.96B
| $1.26M | ﹤0.01% |
32,338
-858
| -3% | -$32K |
|
1911
Enviri
NVRI
$580M
| $1.26M | ﹤0.01% |
75,616
+11,856
| +19% | +$191K |
|
1912
Cannae Holdings
CNNE
$651M
| $1.26M | ﹤0.01% |
35,934
-1,387
| -4% | -$46K |
|
|
SAVE
1913
DELISTED
Spirit Airlines, Inc.
SAVE
| $1.26M | ﹤0.01% |
57,614
+3,288
| +6% | +$76.4K |
|
|
SNBR
1914
DELISTED
Sleep Number
SNBR
| $1.25M | ﹤0.01% |
16,365
-1,020
| -6% | -$85.4K |
|
1915
DNOW Inc
DNOW
$2.98B
| $1.24M | ﹤0.01% |
145,051
-4,991
| -3% | -$43.3K |
|
1916
LivePerson
LPSN
$35.2M
| $1.23M | ﹤0.01% |
2,300
+279
| +14% | +$194K |
|
1917
Oceaneering
OII
$5.24B
| $1.23M | ﹤0.01% |
108,879
+11,999
| +12% | +$155K |
|
1918
Spectrum Brands
SPB
$2.06B
| $1.23M | ﹤0.01% |
12,101
-260
| -2% | -$25.5K |
|
1919
Coty
COTY
$2.48B
| $1.23M | ﹤0.01% |
117,087
-13,422
| -10% | -$126K |
|
1920
Ennis
EBF
$559M
| $1.23M | ﹤0.01% |
62,924
-300
| -0.5% | -$5.8K |
|
1921
NBT Bancorp
NBTB
$2.79B
| $1.23M | ﹤0.01% |
31,872
-4,083
| -11% | -$152K |
|
1922
Kirby Corp
KEX
$7.3B
| $1.22M | ﹤0.01% |
20,550
+653
| +3% | +$36.5K |
|
1923
BioCryst Pharmaceuticals
BCRX
$2.44B
| $1.22M | ﹤0.01% |
87,845
-6,012
| -6% | -$79.6K |
|
1924
First Merchants
FRME
$2.74B
| $1.22M | ﹤0.01% |
29,028
-1,823
| -6% | -$76.4K |
|
1925
S&T Bancorp
STBA
$1.81B
| $1.22M | ﹤0.01% |
38,552
-629
| -2% | -$19.5K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.